Dr Cassandra (Cassie) Hatzipantelis is a postdoctoral research fellow with a keen interest in understanding, developing, and advancing novel therapeutic agents for the treatment of neuropsychiatric disorders. They have a PhD in Drug Discovery Biology from Monash University, Australia where she studied the efficacy and molecular mechanisms of a novel class of therapeutics to treat schizophrenia. Her work during her PhD was critical to the establishment of the Neuromedicines Discovery Centre spin-out biotech company, Phrenix Therapeutics, wherein the pipelines and frameworks Cassie spearheaded the development of are currently in use to design and test novel, safe and effective antipsychotic and procognitive agents. Now in the Olson Lab and as a research fellow for the IPN, Cassie works on various projects related to the pharmacology of psychedelic drugs and their role in neurophysiology, neuropsychiatric pathophysiology, and in the treatment of neuropsychiatric disorders.